Cefotaxime Injection

[05 November 2014]

Products Affected - Description

Claforan injection, Hospira
500 mg vial (NDC 00039-0017-10)

Reason for the Shortage

  • Fresenius Kabi discontinued all cefotaxime presentations in April 2011.
  • Hospira has Claforan on shortage due to manufacturing delays.

Available Products

Cefotaxime injection, West-Ward
500 mg vial (NDC 00143-9930-10)
1 gram vial (NDC 00143-9931-25)
2 gram vial (NDC 00143-9933-25)
10 gram vial (NDC 00143-9935-91)
Claforan injection, Hospira
1 gram vial (NDC 00039-0018-10)
1 gram Add-Vantage vial (NDC 00039-0023-25)
2 gram vial (NDC 00039-0019-10)
2 gram Add-Vantage vial (NDC 00039-0024-25)
10 gram vial (NDC 00039-0020-01)
Claforan injection, Baxter
1 gram frozen premixed bag (NDC 00039-0038-05)
2 gram frozen premixed bags (NDC 00039-0039-05)

Estimated Resupply Dates

Hospira has Claforan 500 mg vials on back order and the company cannot estimate a release date.

Related Shortages


November 5, 2014; October 7, 2014; September 3, 2014; June 24, 2014; April 15, 2014; February 25, 2014; January 14, 2014; December 10, 2013; October 30, 2013; September 30, 2013; August 30, 2013; August 29, 2013; August 1, 2013; July 31, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.